Thymosin Alpha-1: The Immune Peptide With a Long Paper Trail

Thymosin alpha-1 has something most wellness peptides don't: decades of published human research and an approved brand-name drug in other countries. That history is real. It is also routinely stretched to cover claims the research never tested, which is why this peptide deserves a closer read than either its fans or its critics usually give it.

If you have seen thymosin alpha-1 offered as an "immune peptide" for everything from winter colds to post-viral fatigue, this article sorts out what the paper trail actually shows, where it stops, and what questions to ask before anyone prescribes it.

What thymosin alpha-1 is

The thymus is a small gland behind the breastbone where T cells mature. In the 1960s and 1970s, researchers led by Allan Goldstein extracted a mixture of thymic peptides and later isolated a single 28-amino-acid chain from it. That chain became known as thymosin alpha-1. A synthetic version, thymalfasin, was developed as a drug.

In laboratory and clinical studies, thymosin alpha-1 has been reported to influence how T cells and dendritic cells mature and signal, which is why it is described as an immunomodulator rather than a straightforward immune "booster." Modulation can mean nudging a response up in one setting and down in another. That nuance disappears quickly in marketing copy.

Where it is approved, and where it isn't

Thymalfasin has been marketed internationally as Zadaxin. In a 2013 company release, its then-manufacturer SciClone described it as approved in over 30 countries for uses that, depending on local regulators, included hepatitis B, hepatitis C, certain cancers and use as a vaccine adjuvant. China has been a major market.

In the United States the picture is different. Thymalfasin has received orphan drug designations from FDA for specific conditions, which is a program meant to encourage research in rare diseases. Orphan designation is not approval. No thymosin alpha-1 product is FDA-approved, so there is no US labeling that establishes a dose, a population, or a list of contraindications for any use.

Approval somewhere else tells you that a regulator reviewed a dataset for a defined indication. It does not transfer to a different indication, a different population, or a compounded product made from a bulk powder in another country's supply chain.

What the human research found

The "long paper trail" is genuine, but it is uneven. Much of it comes from small trials, open-label studies, and research in populations very different from a healthy adult looking for fewer colds.

Chronic viral hepatitis

Hepatitis B and C were the original clinical focus. Trials over several decades reported mixed results, some favorable, some not, and the treatment landscape has since moved on. Hepatitis C is now curable with direct-acting antivirals, and hepatitis B has well-established antiviral therapies. Thymosin alpha-1 is not a substitute for either.

Sepsis: the TESTS trial

The most rigorous recent test is the TESTS trial (Wu and colleagues, BMJ, 2025), a multicentre, double-blind, placebo-controlled phase 3 trial in adults with sepsis in China. In the main analysis of 1,089 patients, 28-day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo, a hazard ratio of 0.97 that was not statistically significant. The authors concluded the trial found no clear evidence that thymosin alpha-1 decreases 28-day all-cause mortality in adults with sepsis.

That result matters because sepsis is exactly the kind of immune dysregulation where an immunomodulator was expected to help, and earlier smaller studies had been encouraging. When a large, well-run trial doesn't confirm the smaller ones, the larger trial generally deserves more weight.

Cancer, vaccines and COVID-19

Thymosin alpha-1 has been studied as an add-on to cancer treatment and as a vaccine adjuvant, and it was used in some hospitals during the COVID-19 pandemic, with observational reports pointing in different directions. None of this adds up to evidence for routine use outside a trial or a specialist setting, and none of it was designed to answer whether healthy people benefit.

What about safety?

In published trials, thymosin alpha-1 has generally been reported as well tolerated. That is useful context, but it has limits.

• Trials monitor people closely. Tolerability in a supervised trial with a pharmaceutical-grade product does not automatically carry over to a compounded or grey-market vial.
• Immunogenicity is a real question. On its list of bulk substances that may present significant safety risks in compounding, FDA noted that thymosin alpha-1 may pose a significant risk of immunogenicity for certain routes of administration, along with complexities around peptide-related impurities. Immunogenicity means the body may mount an immune response against the peptide itself.
• Immune modulation cuts both ways. People with autoimmune disease, organ transplants, or who take immunosuppressive drugs need specialist input before anything that acts on T cells.
• Pregnancy and breastfeeding have not been adequately studied.

Our article on peptide side effects and what to report explains which reactions are expected, which are not, and how to report them.

Where it stands legally in the US

Because thymosin alpha-1 is not an approved drug, the only lawful pharmacy route would be compounding from a bulk substance, which requires the substance to be eligible under FDA's compounding framework. Thymosin alpha-1 appeared on FDA's list of substances it flagged as raising significant safety risks, and the status of several peptides on that list has changed during 2026. It was not among the seven substances voted on at the July 2026 Pharmacy Compounding Advisory Committee meeting.

We are not going to assert a precise current status, because it has been moving. Rules change; verify with FDA, and expect any prescriber to tell you exactly where thymosin alpha-1 stands on the day you speak with them. Our overview of peptide regulatory status explains the categories, and the research peptide grey market explains why "research use only" vials are a different and riskier thing.

Athletes and drug testing

If you compete in a tested sport, do not assume an immune peptide is outside the rules. The World Anti-Doping Agency's Prohibited List covers peptide hormones and related substances, and a separate category for non-approved substances. How a specific product is classified can depend on its approval status and what it actually contains. Check with USADA or your sport's anti-doping body before using it. See peptides and drug testing.

Questions to ask before anyone prescribes it

If a clinician does propose thymosin alpha-1, the conversation should be able to survive a few direct questions:

1. What specific problem is this meant to address, and what evidence in people like me supports that use?
2. What is its current regulatory status, and how is it being lawfully dispensed today?
3. Which pharmacy prepares it, in which state is that pharmacy licensed, and is it a 503A pharmacy or a 503B outsourcing facility?
4. What would make us stop, and what will we measure to decide whether it is doing anything at all?
5. Who do I contact if I have a reaction, and how quickly will they respond?

Vague answers to any of these are informative. Our list of questions to ask any peptide provider goes further.

Who might reasonably discuss it with a clinician

An honest clinician will usually start somewhere other than the peptide. Frequent infections, slow recovery or persistent fatigue have workable explanations worth ruling out first: iron deficiency, thyroid problems, poor sleep, uncontrolled diabetes, medication effects, or an underlying immune deficiency that needs an immunologist. Vaccination, sleep and treating specific conditions have far better evidence behind them.

If you have been reading about thymosin alpha-1 and want a straight conversation about whether it has any place in your situation, our peptide therapy consultations start with your history and labs, not a product list. The answer may be that it isn't right for you, and we will tell you why.

Common questions

Is thymosin alpha-1 FDA-approved?

No. It has been approved as Zadaxin in other countries for specific indications and has received FDA orphan drug designations, but no thymosin alpha-1 product is approved in the United States.

Does thymosin alpha-1 boost the immune system?

It modulates immune signalling in laboratory and clinical studies of ill patients. There is no good evidence that it makes healthy people less likely to get sick, and in the large TESTS sepsis trial it did not clearly reduce deaths.

Is thymosin alpha-1 the same as TB-500?

No. TB-500 is related to thymosin beta-4, a different molecule with different proposed effects. The shared "thymosin" name is historical.

Can it help with long COVID or chronic fatigue?

We are not aware of controlled trial evidence showing that it does. These conditions deserve a proper medical evaluation, and a clinician can help you look at treatments with better support.

Questions about your own immune health or a peptide you have been offered? Book a consultation and bring what you've read; we'll go through it with you.